Baricitinib, a Janus kinase inhibitor, is currently approved under the brand name Olumiant for the treatment of moderately-to-severely active rheumatoid arthritis.

Compared with foam vehicle, calcipotriol plus betamethasone dipropionate foam offers more rapid and effective itch relief, with associated significant improvements in sleep and Dermatology Life Quality Index scores.

Patients with psoriasis, particularly those with risk factors and severe disease, should receive appropriate screening and preventative intervention.

Overall therapeutic response was statistically higher for patients in the combination therapy group vs either single agent group.

Jeuveau, an aesthetic-only neurotoxin, was evaluated in 2 US Phase 3 placebo-controlled trials and a European and Canadian Phase 3 head-to-head trial vs onabotulinumtoxinA (Botox Cosmetic; Allergan).

Investigators observed differences and similarities in molecular and histopathologic profiles in skin lesions of patients with psoriasis treated with risankizumab vs ustekinumab.

The ACIP and CDC have approved and released 2019 recommendations for the adult immunization schedule in the US.

The investigators sought to determine how the natural environment or diet protects potentially at-risk populations from such allergic conditions as atopic dermatitis.

194 participants with mild to moderate atopic dermatitis were randomly assigned to receive vehicle cream or 0.1%, 0.3%, or 1.0% PAC‐14028 cream twice daily.

Researchers evaluated the efficacy of transplantation of noncultured epidermal cell suspension and noncultured dermal cell suspension vs noncultured epidermal cell suspension alone in patients with vitiligo with duration of clinical stability of 3 to 6 months.